How AI prompting turned writerly description into an everyday skill 
World Cup technology: from ref cams to AI analysts, cutting-edge research is changing the game 
SpaceX Stock Gets $175 Target as Analysts See Massive Growth Ahead 
Today’s space race could turn fatal if we don’t agree on new rules 
Silver Cracks Key 365-Day EMA for First Time Since Feb 2024; Bears Eye $50 on Rallies 
Sell the Bounce": Gold Rally Stalls Near $4165 as Fed Hawks Slam the Door on Rate Cuts — Targets $4000/$3600 
Gold's 365-Day EMA Streak Since Oct 2023 Faces Its First Real Test at $3,980 — Break or Bounce to $4,140? 
How Donald Trump has changed the way diplomacy is done 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
For the past six months US small caps are performing better than large counterparts as measured by Russell 2000 and S&P 500 indices. Since late october 2014, Russell 2000 rose 13.7% compared to 4.4% rise in S&P 500. Chart courtesy Sober look
- Investors remain bullish on US stocks, however exercising cautions over stronger US dollar.
- Large corporate houses that have presence across globe are expected to suffer from stronger US dollar as export revenues and royalty payments will get affected.
- According to EPFR, intelligence provider on Global fund statistics after nearly $31.5 billion withdrawal for the sector in 2014, this year they have started attracting flows. Investors expect small companies to benefit most out of US recovery amid stronger dollar.
- Average sales per share is up 6.6% this year for S&P600 companies so far this year, compared to 0.1% for large caps.
- UBS expects earnings for small companies would be in double digit this year whereas average for large caps would remain in single.
- Investors remain most bullish healthcare and pharmaceuticals whereas energy sector is expected to do worst.
- Bluebird bio returned more than 300% since February 2014, followed by Agios Pharma and Achillion Pharma both of which have returned more than 200%.
